Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Neuroblastoma Pipeline Drugs Market Overview

Neuroblastoma is a cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc.

The Neuroblastoma pipeline market research report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Neuroblastoma Pipeline Products Market Segmentation by Targets

The key targets in the Neuroblastoma pipeline products market are Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and others.

Neuroblastoma Pipeline Products Market Analysis by Targets

Neuroblastoma Pipeline Products Market Analysis by Targets

For more target insights into the Neuroblastoma pipeline products market, download a free report sample

Neuroblastoma Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Neuroblastoma pipeline products market are Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and others.

Neuroblastoma Pipeline Products Market Analysis by Mechanisms of Action

Neuroblastoma Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Neuroblastoma pipeline products market, download a free report sample

Neuroblastoma Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Neuroblastoma pipeline products market are intravenous, oral, parenteral, intraperitoneal, subcutaneous, intratumor, intrathecal, intracerebral, intradermal, intraarterial, and others.

Neuroblastoma Pipeline Products Market Analysis by Routes of Administration

Neuroblastoma Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Neuroblastoma pipeline products market, download a free report sample

Neuroblastoma Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Neuroblastoma pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, synthetic peptide, cell therapy, antisense RNAi oligonucleotide, aptamer, conjugate vaccine, and others.

Neuroblastoma Pipeline Products Market Analysis by Molecule Types

Neuroblastoma Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Neuroblastoma pipeline products market, download a free report sample

Neuroblastoma Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Neuroblastoma pipeline products market are Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc.

Neuroblastoma Pipeline Products Market Analysis by Companies

Neuroblastoma Pipeline Products Market Analysis by Companies

To know more about the leading players in the Neuroblastoma pipeline products market, download a free report sample

Neuroblastoma Pipeline Products Market Report Overview

Key Targets Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and Others
Key Mechanisms of Action Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and Others
Key Routes of Administration Intravenous, Oral, Parenteral, Intraperitoneal, Subcutaneous, Intratumor, Intrathecal, Intracerebral, Intradermal, Intraarterial, and Others
Key Molecule Type Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Oncolytic Virus, Synthetic Peptide, Cell Therapy, Antisense RNAi Oligonucleotide, Aptamer, Conjugate Vaccine, and Others
Leading Companies Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Ability Pharmaceuticals SL
Actuate Therapeutics Inc
ADC Therapeutics SA
Adicet Bio Inc
Advanced Accelerator Applications SA
Advanced Innovative Partners Inc
Advenchen Laboratories LLC
Alaunos Therapeutics Inc
Alissa Pharma
Aptorum Group Ltd
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
AstraZeneca Plc
Athenex Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Bayer AG
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Biocad
BioEclipse Therapeutics Inc
Biogenera SpA
BioLineRx Ltd
Biosceptre International Ltd
Bristol-Myers Squibb Co
Cebiotex SL
Cellectar Biosciences Inc
Chiome Bioscience Inc
Clarity Pharmaceuticals Ltd
Collaborations Pharmaceuticals Inc
CorMedix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DeepCure Inc
DEKK-TEC Inc
DOSE Therapeutics Inc
Edison Oncology Holding Corp
Eli Lilly and Co
Epigene Therapeutics Inc
Epizyme Inc
Exelixis Inc
Expression Therapeutics Inc
F. Hoffmann-La Roche Ltd
GAiA BioMedicine Inc
Gate2Brain SL
Gibson Oncology LLC
GSK plc
Helixmith Co Ltd
Innovent Biologics Inc
Invenra Inc
Ipsen SA
Jubilant DraxImage Inc
KC Pharma LLC
Lantheus Holdings Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Merck & Co Inc
Nanjing CART Medical Technology Co Ltd
Nanogenics Ltd
NanoPharmaceuticals LLC
Nektar Therapeutics
Novartis AG
NovoMedix LLC
Nurix Therapeutics Inc
Nuvalent Inc
OBI Pharma Inc
OGD2 Pharma SAS
Oncolys BioPharma Inc
Onconova Therapeutics Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Open Therapeutics LLC
Orgenesis Inc
Orphelia Pharma SAS
Panbela Therapeutics Inc
Peel Therapeutics Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Progenics Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
PYC Therapeutics Ltd
Qualigen Therapeutics Inc
Recombio SL
Recordati SpA
Ribomic Inc
Rophibio Inc
San Rocco Therapeutics LLC
Sapience Therapeutics Inc
SciTech Development LLC
Secura Bio Inc
Seneca Therapeutics Inc
Senhwa Biosciences Inc
Shionogi & Co Ltd
SignalRx Pharmaceuticals Inc
Sinobioway Cell Therapy Co Ltd
SMTPH Ltd
Sorrento Therapeutics Inc
Statera Biopharma Inc
Stemsynergy Therapeutics Inc
T-Cure Bioscience Inc
Tactiva Therapeutics LLC
TC BioPharm Ltd
Tmunity Therapeutics Inc
Toko Pharmaceutical Industries Co Ltd
Trellis Bioscience Inc
TroBio Therapeutics Pty Ltd
UGISense AG
UTC Therapeutics Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Xcovery Holding Co LLC
Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuroblastoma – Overview

Neuroblastoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neuroblastoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuroblastoma – Companies Involved in Therapeutics Development

Neuroblastoma – Drug Profiles

Neuroblastoma – Dormant Projects

Neuroblastoma – Discontinued Products

Neuroblastoma – Product Development Milestones

Featured News & Press Releases

Oct 28, 2022: Y-mAbs announces scheduling of FDA advisory committee meeting for Omburtamab

Oct 03, 2022: Y-mAbs announces pivotal data for Omburtamab

Sep 26, 2022: Y-mAbs announces regulatory filing for DANYELZA (naxitamab-gqgk) in Brazil

Aug 30, 2022: Y-mAbs and Takeda announces marketing authorization in Israel for DANYELZA (naxitamab-gqgk) for neuroblastoma

Jul 26, 2022: The global pharmaceutical industry is accelerating; Aptorum Group has received orphan drug designation from US FDA for its SACT-1

Jun 28, 2022: SciClone Pharmaceuticals : NMPA approval of IND of DANYELZA (naxitamab) and GM-CSF in combination with Irinotecan and Temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse

Jun 03, 2022: Y-mAbs announces Naxitamab chemoimmunotherapy investigational trial for high-risk neuroblastoma meets primary endpoint

May 31, 2022: Y-mAbs announces FDA Acceptance of Biologics License Application for OMBLASTYS (omburtamab) for the treatment of Neuroblastoma for Priority Review

May 02, 2022: Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to present phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting

May 02, 2022: Aptorum Group updates on data from the completed phase 1 clinical trial of SACT-1, targeting neuroblastoma

Apr 23, 2022: Nektar and collaborators present preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combination with CAR cell therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Apr 20, 2022: Nmpa acceptance of IND of Danyelza (naxitamab) and GM-CSF in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse

Mar 21, 2022: Ascentage Pharma’s MDM2-p53 inhibitor alrizomadlin (APG-115) granted Rare Pediatric Disease Designation by the US FDA for the treatment of neuroblastoma

Feb 11, 2022: Y-mAbs announces completion of Pre-BLA meeting with FDA for Omburtamab

Jan 20, 2022: Aptorum Group receives FDA Orphan Drug Designation for its SACT-1 repurposed drug for the treatment of neuroblastoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Neuroblastoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Neuroblastoma – Dormant Projects, 2022

Neuroblastoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Neuroblastoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Neuroblastoma pipeline products market?

    The key targets in the Neuroblastoma pipeline products market are Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and others.

  • What are the key mechanisms of action in the Neuroblastoma pipeline products market?

    The key mechanisms of action in the Neuroblastoma pipeline products market are Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and others.

  • What are the key routes of administration in the Neuroblastoma pipeline products market?

    The key routes of administration in the Neuroblastoma pipeline products market are intravenous, oral, parenteral, intraperitoneal, subcutaneous, intratumor, intrathecal, intracerebral, intradermal, intraarterial, and others.

  • What are the key molecule types in the Neuroblastoma pipeline products market?

    The key molecule types in the Neuroblastoma pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, synthetic peptide, cell therapy, antisense RNAi oligonucleotide, aptamer, conjugate vaccine, and others.

  • Who are the leading players in the Neuroblastoma pipeline products market?

    The leading companies in the Neuroblastoma pipeline products market are Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc.

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.